Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Human Gene Therapy Clinical Development

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/hum.2017.239PMID 29486604
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Introducing Genes into Mammalian Cells: Viral Vectors.

  2020cited by this paper
• AAV: An Overview of Unanswered Questions

  2017cited by this paper
• Regulatory and Exhausted T Cell Responses to AAV Capsid

  2017cited by this paper
• Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques

  2016cited by this paper
• Systemic delivery of adeno-associated viral vectors.

  2016cited by this paper
• Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications.

  2016cited by this paper
• AAV natural infection induces broad cross-neutralizing antibody responses to multiple AAV serotypes in chimpanzees.

  2016cited by this paper
• Determination of Anti-Adeno-Associated Virus Vector Neutralizing Antibody Titer with an In Vitro Reporter System

  2015cited by this paper
• Prediction of Adeno-Associated Virus Neutralizing Antibody Activity for Clinical Application

  2015cited by this paper
• AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy

  2014influential reference
• Recombinant Adeno-Associated Virus: Efficient Transduction of the Rat VMH and Clearance from Blood

  2014cited by this paper
• Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery.

  2014cited by this paper
• Gene transfer properties and structural modeling of human stem cell-derived AAV.

  2014influential reference
• Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors.

  2013cited by this paper
• Immune responses to AAV vectors: overcoming barriers to successful gene therapy.

  2013cited by this paper
• Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.

  2012cited by this paper
• Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B

  2012cited by this paper
• The advent of AAV9 expands applications for brain and spinal cord gene delivery

  2012cited by this paper
• A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction.

  2011cited by this paper
• Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine

  2011cited by this paper
• Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy.

  2010cited by this paper
• Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

  2010cited by this paper
• The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques.

  2010cited by this paper
• Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

  2009influential reference
• Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration

  2009cited by this paper
• Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.

  2008cited by this paper
• Safety and efficacy of gene transfer for Leber's congenital amaurosis.

  2008cited by this paper
• Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.

  2006cited by this paper
• Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

  2006cited by this paper
• Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.

  2006cited by this paper
• Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues

  2004cited by this paper
• Adeno-associated viruses undergo substantial evolution in primates during natural infections

  2003cited by this paper
• Serologic evidence for human infection with adenovirus-associated viruses.

  1968cited by this paper

• Development of an mRNA replacement therapy for phenylketonuria

  2022cites this paper
• Stent-based delivery of AAV2 vectors encoding oxidation-resistant apoA1

  2022cites this paper
• Natural variations in AAVHSC16 significantly reduce liver tropism and maintain broad distribution to periphery and CNS

  2022cites this paper
• Higher Seroprevalence of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies Among Racial Minorities in the United States

  2021cites this paper
• Sustained Correction of a Murine Model of Phenylketonuria following a Single Intravenous Administration of AAVHSC15-PAH

  2020cites this paper
• Evading the AAV Immune Response in Mucopolysaccharidoses

  2020cites this paper
• Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer

  2018cites this paper